

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

ABSTRACT TEMPLATE

Company: **Pre-Cure** * Website: **www.Pre-Cure.bio***

CEO name: **Dan Simhon**

CATEGORY: **Biotech/Pharma** *

SESSIONS

- **Frontiers in Biochip and Bio-Devices; Advancing Technological Systems with Cutting-Edge Biology**

- Executive Summary

Pre-Cure has developed a unique, multifunctional "tumor-on-a-chip" platform that enables rapid and simultaneous testing of multiple therapies for use in drug development and precision oncology. By integrating advanced tissue engineering, 3D cell culture models, and cutting-edge 3D printing for microfluidic device fabrication, the platform offers a physiologically relevant window into human responses.

- Core Technology ~~What is the technology, its uniqueness, and its value proposition?~~

Pre-Cure's multifunctional "tumor-on-a-chip" platform combines robust, biomimetic microdevices with advanced 3D cancer models derived from human tissues, enabling high-content functional assays under physiologically relevant conditions. By preserving the native tumor microenvironment and replicating the body's dynamic physiological conditions, the platform delivers clinically relevant insights that guide oncologists in treatment selection and empower drug developers to refine and prioritize therapeutic candidates.

- Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Pre-Cure is conducting clinical trials in 6 cancer types in collaboration with 5 leading Israeli medical centers to validate its "tumor-on-a-chip" platform for precision oncology. It also provides advanced 3D cancer models ~~for preclinical drug testing~~ and is developing a unique infrastructure to accelerate treatment response ~~(chemotherapy,~~

Formatted: Normal (Web), Indent: Before: 0.5"

~~radiotherapy and immunotherapy~~ prediction for pharma and AI-driven platforms.

- Business Strategy ~~Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.~~

Pre-Cure is applying its technology through a service-based model. In the near term, the company generates revenue by providing testing services to pharmaceutical companies in Israel. Over the coming year, Pre-Cure plans to establish a laboratory in the U.S. to serve pharma clients and patients.

- What's Next? ~~R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans~~

Pre-Cure is advancing strategic collaborations with pharmaceutical companies and leading hospitals in the U.S. to support clinical validation and market entry. The company will launch its first personalized oncology tests into clinical practice and is developing a proprietary infrastructure to accelerate drug response prediction - serving both pharma partners and AI-driven platforms.